Clin2
NCT07007793Possibly a fitRecruiting

Study of baxdrostat for primary aldosteronism

Primary Hyperaldosteronism

Treatments studied

Part of Hormones & metabolism clinical trials.

This trial tests a new drug called baxdrostat for people with primary aldosteronism, a condition where the adrenal glands make too much aldosterone hormone, often causing high blood pressure. The goal is to see if baxdrostat helps control blood pressure and is safe.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
250 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must be 18 years or older.
  • You must have primary aldosteronism as defined by standard medical guidelines.
  • You must be able to stop taking certain blood pressure medicines (called MRAs or potassium-sparing diuretics) if you are currently taking them.
  • Your kidney function must be good enough (eGFR at least 45).
  • Your blood potassium level must be between 3.0 and 5.0 mmol/L at the start.
  • Your blood pressure must be in a specific range: sitting systolic between 135 and 170 mmHg, and diastolic no higher than 105 mmHg.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07646535Not yet recruiting· Phase 2
SAL0140 study for primary aldosteronism and high blood pressure

This trial tests whether a new drug called SAL0140 can safely lower blood pressure in people with primary aldosteronism, a condition where the body makes too much of a hormone that raises blood pressure. You'll take the study drug at different dose levels while your blood pressure and kidney function are monitored.

Shanghai, Shanghai Municipality
NCT06108427Recruiting
Renin-guided treatment with aldosterone blockers in primary aldosteronism

This study tests whether adjusting a type of blood pressure medication (called a mineralocorticoid receptor antagonist) based on renin levels is safe and helpful for people with primary aldosteronism. It aims to find a better way to manage the condition.

Montreal, Quebec
NCT07686120Not yet recruiting· Phase 3
Study of baxdrostat for Chinese adults with hard-to-treat high blood pressure

This trial is testing if a new medication called baxdrostat can help lower blood pressure in people who are already taking two or more blood pressure medications but still have uncontrolled high blood pressure. It is for Chinese adults only and will compare the study drug to a placebo (inactive pill).

NCT07470983Recruiting· Phase 2
Study of HRS-1780 for Primary Aldosteronism

This trial tests a new drug called HRS-1780 for people with primary aldosteronism, a condition that causes high blood pressure. The goal is to see if the drug is safe and effective in lowering blood pressure and managing the condition.

Chongqing, Chongqing Municipality
NCT07550465Not yet recruiting· Phase 2
QLS1410 for treating primary aldosteronism

This study tests a new medication (QLS1410) for primary aldosteronism, a condition where the body produces too much of a hormone called aldosterone, causing high blood pressure. The trial will see if this drug can help control blood pressure better than current treatments.

NCT05688579Enrolling by invitation· Phase 4
Testing an aldosterone-blocking medicine in hard-to-control hypertension

This trial studies whether a medicine that blocks aldosterone (called an MRA) can improve cardiovascular outcomes in people with high aldosterone levels and high blood pressure. You may be asked to take the study medicine and have blood pressure, heart, and lab tests monitored over time.

Ürümqi, Xinjiang

Hear when a new Primary Hyperaldosteronism trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.